US · Healthcare · Biotechnology
EPS came in at -0.70 against a street estimate of -0.73 — a beat of 4.1%.
Analysts rate Belite Bio Inc ADR a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $228.89.
| Fund | Stake |
|---|---|
| Darwin Global Management, Ltd. | 7.64% |
| Paradigm Biocapital Advisors LP | 3.06% |
| RTW INVESTMENTS, LLC | 1.78% |
| Millennium Management LLC | 1.23% |
| Maverick Capital Ltd | 0.98% |
| Eventide Asset Management, LLC | 0.97% |
| Deerfield Management Co | 0.89% |
| Holocene Advisors, LP | 0.62% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On September 8, 2026, Belite Bio announced that it submitted a New Drug Application (NDA) in Japan for tinlarebant to treat Starga | 2026-09-08 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • FDA accepted Belite Bio’s New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) and granted Priority Revi | 2026-08-13 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On August 11, 2026, Belite Bio announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) | 2026-08-11 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • On June 12, 2026, Belite Bio announced that it completed the rolling submission of a New Drug Application (NDA) to the U.S. Food a | 2026-06-15 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Belite Bio is a clinical-stage biotechnology company with no products approved for commercial sale. • Its lead product candidate | 2026-03-31 |
| Annual report FY2024 (20-F) | 2025-03-17 |
| Annual report FY2023 (20-F) | 2024-03-12 |
| Annual report FY2022 (20-F) | 2023-03-31 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Belite Bio Inc ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.